– Romania currently provides twice as many innovative drugs to its beneficiaries of health insurance, whereas the availability of innovative therapies through reimbursement lists in Bulgaria and Croatia is around three to three and a half times bigger than in Serbia – our interviewee notes, but also adds that, regardless of this, there's no reason not to believe the officials when they say that this should change.
– We expect new additions to the list in 2018, as well as in the upcoming years. It is only if there are at least twenty new innovative drugs on the list each year in the upcoming period that we might expect the availability of these drugs in Serbia to be at least equal to that of the neighboring countries at the moment.
When asked what criteria the state should use in approving innovative products, our interviewee says that expert committees of the NHIF and the Ministry of Health are in charge of this and that, from the angle of the industry, the most important thing is to take care of the areas in which the country is lagging behind the golden standard of treatment in Europe and the world the most, as well as the most frequent and the most lethal diseases in Serbia.Servier
also points out that Serbia is still developing pharmaco-economic models for putting products on the reimbursement list.
– The price shouldn't be the only criterion for approving innovative products. Other criteria, such as savings realized by reducing the number of hospitalizations or achieving better disease control through implementing innovative therapies should also be considered – the pharmaceutical company, whose hypertension and diabetes medicines are already on the reimbursement list, points out.
This company, headquartered in France, is one of the leaders in therapies for hypertension, angina pectoris and diabetes. It invests 25% of its total sales in research and development, and has been at the very top of the list of fast-growing innovative companies in Serbia in the past two years.
At the moment, as they announce for eKapija, they are working on providing the Serbian market with a new oncology product as well, and they will also cooperate with healthcare authorities to the end of having the said drug included on the reimbursement list.